This study demonstrated that crizotinib plus bevacizumab showed benefit in treating naive ALK rearrangement NSCLC patients, and the toxicity was relatively tolerant. Our results suggested that crizotinib plus bevacizumab might be a promising treatment strategy in ALK/ROS-1/c-MET positive NSCLC patients. READ ARTICLE
American Journal of Translational Research DOI:10.1016/j.cllc.2021.06.011
Authors: Huang Z., Xiong Q., Cui Z., Tao H., Zhang S., Wang L., Cui P., Chen S., Huang D., Yang B., Hu Y.